Skip to content

asancpt/BE-apps

Repository files navigation

Introduction

To assess bioequivalence, the 90% confidence interval for the difference in the means of the log-transformed data should be calculated using appropriate methods to the study design. The antilogs (exponents) of the confidence limits obtained constitute the 90% confidence interval for the ratio of the geometric means between the T and R products. [@fda;@chow;@hauschke] To establish bioequivalence, the calculated confidence interval should fall within a bioequivalence limit, usually 80-125% for the ratio of the product averages. For nonreplicated crossover designs, general linear model procedures available in PROC GLM in SAS are preferred, although linear mixed-effects model procedures can also be indicated for analysis. [@fda]

BE R package [@R-BE] can analyze bioequivalence study data with industrial strength. The current version of BE performs bioequivalency tests for several pharmacokinetic parameters of the conventional two-treatment, two-period, two-sequence (2x2) randomized crossover design. The statistical model includes factors accounting for the following sources of variation: sequence (SEQ), subjects nested in sequences (SUBJ(SEQ)), period (PRD), and treatment (TRT).

In this document, the author performed validation of bioequivalence tests performed by BE R package as compared to bioequivalence tests performed by PROC GLM or PROC MIXED in SAS.

Poster

Results

## $AUClast
## $AUClast$`Analysis of Variance (log scale)`
##                          SS DF           MS           F            p
## SUBJECT        2.875497e+00 32 8.985928e-02 3.183942248 0.0008742828
## GROUP          1.024607e-01  1 1.024607e-01 1.145416548 0.2927731856
## SUBJECT(GROUP) 2.773036e+00 31 8.945279e-02 3.169539016 0.0009544080
## PERIOD         3.027399e-05  1 3.027399e-05 0.001072684 0.9740824428
## DRUG           3.643467e-02  1 3.643467e-02 1.290972690 0.2645764201
## ERROR          8.749021e-01 31 2.822265e-02          NA           NA
## TOTAL          3.786834e+00 65           NA          NA           NA
## 
## $AUClast$`Between and Within Subject Variability`
##                                 Between Subject Within Subject
## Variance Estimate                    0.03061507     0.02822265
## Coefficient of Variation, CV(%)     17.63193968    16.91883011
## 
## $AUClast$`Least Square Means (geometric mean)`
##                 Reference Drug Test Drug
## Geometric Means       5092.098  4858.245
## 
## $AUClast$`90% Confidence Interval of Geometric Mean Ratio (T/R)`
##                  Lower Limit Point Estimate Upper Limit
## 90% CI for Ratio    0.889436      0.9540753    1.023412
## 
## $AUClast$`Sample Size`
##                       True Ratio=1 True Ratio=Point Estimate
## 80% Power Sample Size            6                         7
## 
## 
## $Cmax
## $Cmax$`Analysis of Variance (log scale)`
##                          SS DF           MS           F          p
## SUBJECT        2.861492e+00 32 8.942162e-02 2.237604579 0.01367095
## GROUP          9.735789e-05  1 9.735789e-05 0.001054764 0.97429977
## SUBJECT(GROUP) 2.861394e+00 31 9.230304e-02 2.309706785 0.01131826
## PERIOD         4.717497e-03  1 4.717497e-03 0.118046317 0.73348258
## DRUG           6.837756e-03  1 6.837756e-03 0.171101730 0.68198228
## ERROR          1.238856e+00 31 3.996310e-02          NA         NA
## TOTAL          4.112258e+00 65           NA          NA         NA
## 
## $Cmax$`Between and Within Subject Variability`
##                                 Between Subject Within Subject
## Variance Estimate                    0.02616997      0.0399631
## Coefficient of Variation, CV(%)     16.28355371     20.1921690
## 
## $Cmax$`Least Square Means (geometric mean)`
##                 Reference Drug Test Drug
## Geometric Means       825.5206  808.8778
## 
## $Cmax$`90% Confidence Interval of Geometric Mean Ratio (T/R)`
##                  Lower Limit Point Estimate Upper Limit
## 90% CI for Ratio   0.9013625      0.9798396    1.065149
## 
## $Cmax$`Sample Size`
##                       True Ratio=1 True Ratio=Point Estimate
## 80% Power Sample Size            8                         8
## 
## 
## $Tmax
## $Tmax$`Wilcoxon Signed-Rank Test`
##   p-value 
## 0.2326894 
## 
## $Tmax$`Hodges-Lehmann Estimate`
##                            Lower Limit Point Estimate Upper Limit
## 90% Confidence Interval       -0.33000       -0.03500      0.1050
## 90% Confidence Interval(%)    74.37661       97.28237    108.1529

Plot

AUClast

Cmax

Tmax

References

sessionInfo()
## R version 3.6.3 (2020-02-29)
## Platform: x86_64-w64-mingw32/x64 (64-bit)
## Running under: Windows 10 x64 (build 17763)
## 
## Matrix products: default
## 
## locale:
## [1] LC_COLLATE=Korean_Korea.949  LC_CTYPE=Korean_Korea.949   
## [3] LC_MONETARY=Korean_Korea.949 LC_NUMERIC=C                
## [5] LC_TIME=Korean_Korea.949    
## 
## attached base packages:
## [1] stats     graphics  grDevices utils     datasets  methods   base     
## 
## other attached packages:
## [1] knitr_1.28
## 
## loaded via a namespace (and not attached):
##  [1] compiler_3.6.3  magrittr_1.5    tools_3.6.3     htmltools_0.4.0
##  [5] Rcpp_1.0.4.6    stringi_1.4.6   rmarkdown_2.1   stringr_1.4.0  
##  [9] xfun_0.12       digest_0.6.25   rlang_0.4.5     evaluate_0.14